Aytu BioPharma Inc. (NASDAQ:AYTU) Receives Consensus Recommendation of “Hold” from Analysts

Shares of Aytu BioPharma Inc. (NASDAQ:AYTU) have received a consensus rating of “Hold” from the five brokerages that are covering the stock, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation and three have assigned a buy recommendation to the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $9.3333.

A number of equities research analysts have recently commented on the company. Zacks Research downgraded Aytu BioPharma from a “hold” rating to a “strong sell” rating in a research report on Friday, January 30th. Wall Street Zen raised Aytu BioPharma to a “hold” rating in a report on Saturday, February 7th. Ascendiant Capital Markets lifted their price target on Aytu BioPharma from $12.50 to $13.00 and gave the stock a “buy” rating in a research note on Wednesday, December 10th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Aytu BioPharma in a report on Friday, January 9th.

Aytu BioPharma Trading Down 2.3%

AYTU stock opened at $2.13 on Monday. The company has a quick ratio of 1.03, a current ratio of 1.16 and a debt-to-equity ratio of 0.70. The company has a market cap of $22.85 million, a price-to-earnings ratio of -0.55 and a beta of 0.37. The business has a fifty day simple moving average of $2.53 and a 200-day simple moving average of $2.33. Aytu BioPharma has a 52 week low of $0.95 and a 52 week high of $3.07.

Aytu BioPharma (NASDAQ:AYTU) last announced its quarterly earnings results on Tuesday, February 3rd. The company reported ($1.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.79). Aytu BioPharma had a negative return on equity of 28.22% and a negative net margin of 39.02%.The business had revenue of $15.17 million for the quarter, compared to analysts’ expectations of $12.17 million.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of AYTU. DRW Securities LLC acquired a new stake in Aytu BioPharma during the 4th quarter valued at $76,000. Bellevue Asset Management LLC bought a new stake in shares of Aytu BioPharma during the fourth quarter worth $65,000. Daytona Street Capital LLC bought a new stake in shares of Aytu BioPharma during the fourth quarter worth $26,000. FNY Investment Advisers LLC increased its stake in shares of Aytu BioPharma by 24,207.7% in the fourth quarter. FNY Investment Advisers LLC now owns 31,600 shares of the company’s stock valued at $82,000 after buying an additional 31,470 shares in the last quarter. Finally, Two Sigma Investments LP increased its stake in shares of Aytu BioPharma by 96.2% in the third quarter. Two Sigma Investments LP now owns 68,736 shares of the company’s stock valued at $129,000 after buying an additional 33,701 shares in the last quarter. 33.49% of the stock is owned by institutional investors.

Aytu BioPharma Company Profile

Aytu BioPharma, Inc is a specialty pharmaceutical company focused on the development, licensing and commercialization of novel therapeutics to address underserved medical needs. Headquartered in Englewood, Colorado, Aytu pursues a strategy of acquiring late-stage or approved products in areas such as urology, endocrinology, women’s health, pediatric care and supportive therapies. The company leverages in-house commercialization capabilities and targeted business development to build a diversified portfolio of prescription medicines and diagnostics.

Aytu’s marketed portfolio includes Natesto, a nasal testosterone gel for treatment of male hypogonadism; ZolpiMist, a zolpidem tartrate lingual spray for the short-term treatment of insomnia; and Tuzistra XR, an extended-release cough syrup formulation indicated for relief of cough and upper respiratory symptoms.